Skip to content

Study · Non-randomized trial · n = 36 · 1987

4 results

Salmon calcitonin in the therapy of corticoid-induced osteoporosis.

Ringe JD, Welzel D

European journal of clinical pharmacology1 Jan 1987Cited by 94 (Europe PMC)

PMID3319638 (opens in a new tab)DOI10.1007/bf00610377 (opens in a new tab)PepBankPUB-03319638
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In steroid-dependent lung disease with osteoporosis, cortical bone mineral increased 2.6% with salmon calcitonin versus a 1.4% decrease in controls.

    In plain wordsIn steroid-dependent lung disease with osteoporosis, cortical bone mineral increased with salmon calcitonin and decreased in controls.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseCortical bone mineral content
    Study

    n = 36

    Comparator
    Untreated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 I.U. every other day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Cortical bone mineral content change
    2.6%
    salmon calcitonin
    Cortical bone mineral content change
    −1.4%
    controls

    Source sentences

    Summary
    In the controls there were significant decrements of 1.4% and 3.5%, respectively, in cortical and cortical and trabecular bone mineral content, whereas in subjects on calcitonin there were increments of 2.6% and 2.7%, respectively.
    2 context sentences
    Summary · context
    Thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis have been studied, of whom 18 were treated with salmon calcitonin and the other 18 served as controls.
    Summary · context
    Treatment lasted for 6 months and consisted of 100 I.U.s.c. every other day.
  2. 02HumanNon-randomized trialEfficacy outcome

    In steroid-dependent lung disease with osteoporosis, cortical and trabecular bone mineral increased 2.7% with calcitonin versus a 3.5% decrease in controls.

    In plain wordsIn steroid-dependent lung disease with osteoporosis, cortical and trabecular bone mineral increased with calcitonin and decreased in controls.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseCortical and trabecular bone mineral content
    Study

    n = 36

    Comparator
    Untreated controls
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 I.U. every other day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Cortical and trabecular bone mineral content change
    2.7%
    salmon calcitonin
    Cortical and trabecular bone mineral content change
    −3.5%
    controls

    Source sentences

    Summary
    In the controls there were significant decrements of 1.4% and 3.5%, respectively, in cortical and cortical and trabecular bone mineral content, whereas in subjects on calcitonin there were increments of 2.6% and 2.7%, respectively.
    2 context sentences
    Summary · context
    Thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis have been studied, of whom 18 were treated with salmon calcitonin and the other 18 served as controls.
    Summary · context
    Treatment lasted for 6 months and consisted of 100 I.U.s.c. every other day.
  3. 03HumanNon-randomized trialEfficacy outcome

    In steroid-dependent lung disease with osteoporosis, salmon calcitonin treatment reduced the incidence of new fractures during observation.

    In plain wordsIn steroid-dependent lung disease with osteoporosis, salmon calcitonin treatment reduced new fractures.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseNew fractures
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    100 I.U. every other day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Additional evidence of positive effect of calcitonin was derived from the reduced incidence of new fractures occurring during the observation period.
    2 context sentences
    Summary · context
    Thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis have been studied, of whom 18 were treated with salmon calcitonin and the other 18 served as controls.
    Summary · context
    Treatment lasted for 6 months and consisted of 100 I.U.s.c. every other day.
  4. 04HumanNon-randomized trialEfficacy outcome

    In steroid-dependent lung disease with osteoporosis, salmon calcitonin treatment significantly reduced back pain.

    In plain wordsIn steroid-dependent lung disease with osteoporosis, salmon calcitonin treatment significantly reduced back pain.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseBack pain
    Study

    n: not reported in source

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    100 I.U. every other day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    A significant reduction in back pain was a further consequence of the hormone therapy.
    2 context sentences
    Summary · context
    Thirty-six patients with steroid-dependent, chronic obstructive lung disease and associated steroid osteoporosis have been studied, of whom 18 were treated with salmon calcitonin and the other 18 served as controls.
    Summary · context
    Treatment lasted for 6 months and consisted of 100 I.U.s.c. every other day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.